# A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage

Source: https://onco.cc/trials/nct05353257/  
OnCo record `nct05353257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Serplulimab, Carboplatin in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05353257 by Shanghai Henlius Biotech, with 511 participants enrolled, started 2022-05-17 and due to reach its primary completion in 2026-06-30. Interventions recorded: HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI). Conditions listed: Limited-Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05353257
- Phase: 3
- Setting: A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of Serplulimab or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 511

## Sources

- ClinicalTrials.gov NCT05353257: https://clinicaltrials.gov/study/NCT05353257

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct05353257.json